Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

Next Previous
Trial Profile

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Silmitasertib (Primary) ; Antineoplastics; Irinotecan; Temozolomide; Vincristine
  • Indications Ewing's sarcoma; Liposarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 May 2025 Planned number of patients changed from 114 to 104.
  • 06 Nov 2024 According to a Senhwa Biosciences media release, funding for this clinical trial is provided by the Beat Childhood Cancer Foundation and the Little Warrior Foundation. Funding for Behura's research which led to the clinical trial was provided by Four Diamonds. Dr. Chandrika Behura is the study chair and principal investigator.
  • 06 Nov 2024 According to a Senhwa Biosciences media release, first patient has been enrolled at the trial center- Penn State Health Children's Hospital in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top